Original Article

The prognostic value of combined clinicopathological and biomarker modelling for non-muscle-invasive bladder cancer

Corresponding Author

Chin-Chen Pan

Department of Pathology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

Address for correspondence: C-C Pan, MD, Department of Pathology, Taipei Veterans General Hospital, No. 201, Shi-Pai Road, Section 2, Taipei 11217, Taiwan. e-mail: [email protected]Search for more papers by this author

Hui-Jung Yu,

Hui-Jung Yu

Department of Pathology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan

Search for more papers by this author

Yen-Hwa Chang,

Yen-Hwa Chang

Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Search for more papers by this author

Chin-Chen Pan,

Corresponding Author

Chin-Chen Pan

Department of Pathology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

Hui-Jung Yu,

Hui-Jung Yu

Department of Pathology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan

Search for more papers by this author

Yen-Hwa Chang,

Yen-Hwa Chang

Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan

Search for more papers by this author

First published: 04 February 2014

https://doi.org/10.1111/his.12385

Citations: 2

Share a link

Email
Wechat
Bluesky

Abstract

Aims

To construct a prognostic model, incorporating clinicopathological variables and biomarkers, to predict recurrence, progression and cancer-specific mortality for patients who have undergone transurethral resection of non-muscle-invasive bladder cancer (NMIBC).

Methods and results

A total of 12 biomarkers were evaluated using immunohistochemical analysis of tissue arrays of 605 NMIBCs. Competing risk analyses were performed to derive prognostic indices and nomograms. In addition to the 2004 WHO histological grade and intravesical instillation status, five biomarkers (i.e. Ki-67, p53, cyclin D1, cyclooxygenase-2 and heat shock protein-27) were selected on the grounds of independent statistical significance. Based on the prognostic model, four distinct risk groups were discerned. NMIBC patients with extensive lamina propria invasion (T1_e) had the highest risk. Patients with non-invasive and focal lamina propria-invasive NMIBCs (Ta/T1_f) with a high prognostic index showed a risk approaching or equivalent to that of patients with T1_e tumours. Patients with Ta/T1_f NMIBCs with low indices were mostly indolent, while those with intermediate indices had a risk in between that observed for T1_e and Ta/T1_f NMIBCs tumours.

Conclusions

Robust risk tables and nomograms were created to predict an overall perspective of disease outcomes, which may aid in developing individualized follow-up programmes.

Supporting Information

References

1Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Tumours of the urinary system. In P Kleihue, L Sobin eds. World Health Organization classification of tumours. Lyon: IARC Press, 2004; 89–123.
Google Scholar
2Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am. J. Clin. Pathol. 2010; 133; 788–795.
10.1309/AJCP12MRVVHTCKEJ
PubMed Web of Science® Google Scholar
3Comperat E, Egevad L, Lopez-Beltran A et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology 2013; 63; 756–766.
10.1111/his.12214
PubMed Web of Science® Google Scholar
4Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J. Urol. 2002; 168; 968–972.
10.1016/S0022-5347(05)64553-3
PubMed Web of Science® Google Scholar
5Cheng L, Lopez-Beltran A, Bostwick DG. Tissue-based biomarkers. In L Cheng, A Lopez-Beltran, DG Bostwick eds. Bladder pathology. Hoboken: Wiley-Blackwell, 2013; 679–706.
Google Scholar
6Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R. Bladder cancer: translating molecular genetic insights into clinical practice. Hum. Pathol. 2011; 42; 455–481.
10.1016/j.humpath.2010.07.007
CAS PubMed Web of Science® Google Scholar
7Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology 2010; 57; 1–13.
10.1111/j.1365-2559.2010.03592.x
CAS PubMed Web of Science® Google Scholar
8Chang WC, Chang YH, Pan CC. Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection. Am. J. Surg. Pathol. 2012; 36; 454–461.
10.1097/PAS.0b013e31823dafd3
PubMed Web of Science® Google Scholar
9Pan CC, Chen PC, Chiang H. An easy method for manual construction of high-density tissue arrays. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 370–372.
10.1097/00129039-200412000-00015
PubMed Web of Science® Google Scholar
10Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999; 94; 496–509.
10.1080/01621459.1999.10474144
Web of Science® Google Scholar
11Bertz S, Denzinger S, Otto W et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer – evaluation of a large hospital-based single-centre series. Histopathology 2011; 59; 722–732.
10.1111/j.1365-2559.2011.03989.x
CAS PubMed Web of Science® Google Scholar
12Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86; 1035–1043.
10.1002/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D
CAS PubMed Web of Science® Google Scholar
13Orsola A, Trias I, Raventos CX et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur. Urol. 2005; 48; 231–238.
10.1016/j.eururo.2005.04.013
CAS PubMed Web of Science® Google Scholar
14van der Aa MN, van Leenders GJ, Steyerberg EW et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol. 2005; 36; 981–986.
10.1016/j.humpath.2005.06.017
CAS PubMed Web of Science® Google Scholar
15van Rhijn BW, Van der Kwast TH, Alkhateeb SS et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur. Urol. 2012; 61; 378–384.
10.1016/j.eururo.2011.10.026
PubMed Web of Science® Google Scholar
16Fristrup N, Birkenkamp-Demtroder K, Reinert T et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am. J. Pathol. 2013; 182; 339–349.
10.1016/j.ajpath.2012.10.017
CAS PubMed Web of Science® Google Scholar
17Shariat SF, Karakiewicz PI, Ashfaq R et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112; 315–325.
10.1002/cncr.23162
PubMed Web of Science® Google Scholar
18Shariat SF, Chade DC, Karakiewicz PI et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol. 2010; 183; 68–75.
10.1016/j.juro.2009.08.115
PubMed Web of Science® Google Scholar
19Bush C, Price P, Norton J et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br. J. Cancer 1991; 64; 357–360.
10.1038/bjc.1991.306
PubMed Web of Science® Google Scholar
20Lee AK, Wiley B, Loda M et al. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma. Mod. Pathol. 1992; 5; 61–67.
CAS PubMed Web of Science® Google Scholar
21Mulder AH, Van Hootegem JC, Sylvester R et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J. Pathol. 1992; 166; 37–43.
10.1002/path.1711660107
CAS PubMed Web of Science® Google Scholar
22Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253; 49–53.
10.1126/science.1905840
CAS PubMed Web of Science® Google Scholar
23Vriesema JLJ, Witjes JA, Debruyne FMJ, Schalken JA. Value of analyzing p53 status, or other objective markers, when determing management strategies. In CS Foster, JS Ross eds. Pathology of the urinary bladder. Philadelphia: Saunders, 2004; 269–282.
Google Scholar
24Lee CC, Yamamoto S, Morimura K et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997; 79; 780–789.
10.1002/(SICI)1097-0142(19970215)79:4<780::AID-CNCR15>3.0.CO;2-W
CAS PubMed Web of Science® Google Scholar
25Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br. J. Cancer 2001; 84; 270–275.
10.1054/bjoc.2000.1557
CAS PubMed Web of Science® Google Scholar
26Yang CC, Chu KC, Chen HY, Chen WC. Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression. Urol. Int. 2002; 69; 190–194.
10.1159/000063945
CAS PubMed Web of Science® Google Scholar
27Sweeney CJ, Marshall MS, Barnard DS et al. Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect. Prev. 2002; 26; 238–244.
10.1016/S0361-090X(02)00064-8
CAS PubMed Web of Science® Google Scholar
28Mohammed SI, Knapp DW, Bostwick DG et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999; 59; 5647–5650.
CAS PubMed Web of Science® Google Scholar
29Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 2003; 169; 938–942.
10.1097/01.ju.0000043638.89552.ed
CAS PubMed Web of Science® Google Scholar
30Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl Cancer Inst. 2000; 92; 1564–1572.
10.1093/jnci/92.19.1564
CAS PubMed Google Scholar
31Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 1993; 259; 1409–1410.
10.1126/science.8451637
CAS PubMed Web of Science® Google Scholar
32Yu HJ, Chang YH, Pan CC. Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder. Histopathology 2013; 62; 788–798.
10.1111/his.12087
CAS PubMed Web of Science® Google Scholar
33Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J. Clin. Pathol. 2010; 63; 910–915.
10.1136/jcp.2010.079764
PubMed Web of Science® Google Scholar

Citing Literature

Volume65, Issue2

August 2014

Pages 207-215

The prognostic value of combined clinicopathological and biomarker modelling for non-muscle-invasive bladder cancer

Abstract

Aims

Methods and results

Conclusions

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

The prognostic value of combined clinicopathological and biomarker modelling for non-muscle-invasive bladder cancer

Abstract

Aims

Methods and results

Conclusions

Supporting Information

References

Citing Literature

References

Related

Information